- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04671849
Un estudio clínico abierto, multicéntrico, de fase I para evaluar la seguridad, la eficacia y las características farmacocinéticas de SIM1803-1A en pacientes con tumores sólidos localmente avanzados/metastásicos con mutaciones de fusión del gen NTRK, ROS1 o ALK.
This research study is done to test the safety, effectiveness and pharmacokinetic characteristics of SIM1803-1A in patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK gene fusion mutations. The cancer must have a change in a particular gene (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these NTRK/ ROS1 /ALK genes in cancer cells and can therefore be used to treat cancer.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Shanghai, Porcelana
- Shanghai Chest Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists;Proof of a malignancy harboring a NTRK、ROS1 or ALK fusion;Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 and a life expectancy of at least 3 month;Adequate hematologic, hepatic, and renal function;Signed informed consent form;
Exclusion Criteria:
- Any contraindications as listed in the local approved product information;Patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible;Pregnancy or lactation;Clinically significant active cardiovascular disease or history of myocardial infarction;Participation in an investigational program with interventions outside of routine clinical practice;Prior treatment with other kinase inhibitor with tropomyosin receptor kinase inhibition;Active uncontrolled systemic bacterial, viral, or fungal infection;Current treatment with a strong CYP3A4 inhibitor or inducer;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: pacientes adultos_Dosis 1
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 2
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 3
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 4
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 5
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 6
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 7
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
|
Experimental: pacientes adultos_Dosis 8
|
SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with adverse events
Periodo de tiempo: 5 years
|
Number of participants with adverse events |
5 years
|
|
Severity of adverse events
Periodo de tiempo: 5 years
|
Severity of adverse events |
5 years
|
|
Maximum tolerated dose
Periodo de tiempo: 5 years
|
Maximum tolerated dose |
5 years
|
|
Recommended dose for dose expansion
Periodo de tiempo: 5 years
|
Recommended dose for dose expansion |
5 years
|
|
Maximum concentration of SIM1803-1A in plasma (Cmax)
Periodo de tiempo: Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Maximum concentration of SIM1803-1A in plasma (Cmax) |
Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)
Periodo de tiempo: Up to 1 day
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted) |
Up to 1 day
|
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted)
Periodo de tiempo: Up to 3 days
|
Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted) |
Up to 3 days
|
|
Number of participants with treatment-emergent adverse events (TEAEs)
Periodo de tiempo: Up to 24 weeks
|
Number of participants with treatment-emergent adverse events (TEAEs) |
Up to 24 weeks
|
|
Time to maximum concentration of SIM1803-1A in plasma (Tmax)
Periodo de tiempo: Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Time to maximum concentration of SIM1803-1A in plasma (Tmax) |
Predose and 0.25, 0.5, 1, 2, 4, 8,12,24and 48 hours after drug administration on Days 1 and 8 of Cycle 1(each cycle is 21 days)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Response Rate (ORR)
Periodo de tiempo: Up to 60 months
|
Overall Response Rate (ORR) |
Up to 60 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to 60 months
|
Duration of Response (DOR) |
Up to 60 months
|
|
progression-free survival(PFS)
Periodo de tiempo: Up to 60 months
|
progression-free survival(PFS) |
Up to 60 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: shun lu, Ph.D, Shanghai Chest Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- SIM1803-1A-NTRK-0101
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .